Replies to post #11790 on RespireRx Pharmaceuticals Inc (fka RSPI)

[neuroinv]

Excellent example--another surrogate marker being used as a shortcut to quasi-POC.
This is an option for Cortex on their own, I have no idea which marker (PET or EEG) would be considered more substantive. The best surrogate marker (at least from a market perspective) is beta-amyloid load, but there's no reason to expect that to change with CX701.

NeuroInvestment

[davidal66]

So, Cortex could do the Ia with CX717 in the healthy young population, and then do a phase Ib in the elderly, adding qEEG to show a marker of cognitive effect. Animal data can then be combined looked at with QEEG in animals with Aricept plus CX701 and CX1763. Should the histology issue not be a problem with CX701, 1763 toxicology testing, and the Ia/Ib program suggests a benifit, and should the PET data with CX717 look compelling, this is a road to a decent partnership for Alzheimer's and neurodegeneration. Such a deal would include ADHD and other conditions as well. The question is when to seek such a deal... at what stage should Cortex seek such a deal... sooner or later. I vote sooner=).